Status:
COMPLETED
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist
Lead Sponsor:
Neurogastrx, Inc.
Conditions:
Overweight and Obesity
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
Adult participants with BMI between 22 - 35 kg/m2 will be enrolled and randomized to receive either NG101 (20 mg twice daily \[BID\]) or placebo for 5 days beginning on Day 1. On Day 2, all participan...
Eligibility Criteria
Inclusion
- Healthy adult
- Male or female
- BMI between 22 - 35 kg/m2 at screening
Exclusion
- Presence or history of illness that might confound the results of the study or pose an -
- History of presence of gastroparesis, gallbladder disease, acute or chronic pancreatitis, or surgery of the abdomen
- History or presence of Type 1 or Type 2 diabetes
Key Trial Info
Start Date :
June 24 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 13 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06500429
Start Date
June 24 2024
End Date
September 13 2024
Last Update
September 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Celerion
Tempe, Arizona, United States, 85283